Thuy-Tien T Nguyen, William P Katt, Richard A Cerione. Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies.Future drug discovery. 2023, 4 (4): FDD79
Marco Cabrera, Meghana Kolli, Meena Jaggi, Subhash C Chauhan, Murali M Yallapu. miRNA-205: a future therapeutic molecule for liver diseases.Future drug discovery. 2023, 4 (3): FDD78
Birgit Caspar, Pietro Cocchiara, Armelle Melet, Kristof Van Emelen, Annegret Van der Aa, Graeme Milligan, Jean-Philippe Herbeuval. CXCR4 as a novel target in immunology: moving away from typical antagonists.Future drug discovery. 2022, 4 (2): FDD77
Gabrielle Brewer, Anne-Marie Fortier, Morag Park, Christopher Moraes. The case for cancer-associated fibroblasts: essential elements in cancer drug discovery?Future drug discovery. 2022, 4 (1): FDD71
Colin J Suckling, Iain S Hunter, Fraser J Scott. Multitargeted anti-infective drugs: resilience to resistance in the antimicrobial resistanceĀ era.Future drug discovery. 2022, 4 (1): FDD73
Vivek K Kashyap, Anupam Dhasmana, Murali M Yallapu, Subhash C Chauhan, Meena Jaggi. as a potential future drug molecule for COVID-19.Future drug discovery. 2020, 2 (4): FDD50
Eric Ni, Eehjoe Kwon, Lauren M Young, Klara Felsovalyi, Jennifer Fuller, Timothy Cardozo. How polypharmacologic is each chemogenomics library?Future drug discovery. 2020, 2 (1): FDD26
Lai Wei, Xueliang Pan, Soledad Fernandez. Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials.Future drug discovery. 2019, 1 (2): FDD18
Vidhi Khanna, Stephen Kalscheuer, Ameya Kirtane, Wenqiu Zhang, Jayanth Panyam. Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer.Future drug discovery. 2019, 1 (1): FDD8